Economics of Cancer Medicines: For Whose Benefit?

New Bioethics

Volumn 23, Issue 1, 2017, Pages 95-104

  Gyawali, Bishal ^a   Sullivan, Richard ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Hammersmith Hospital Campus   (United Kingdom)

Author keywords

cancer drugs; financial toxicity; low middle income countries; pharmacoeconomics; value; WHO essential medicine list

Indexed keywords

ANTINEOPLASTIC AGENT;

COST; DEVELOPING COUNTRY; ECONOMICS; HUMAN; INCOME; INDUSTRY; NEOPLASM; POLITICS; POVERTY; SOCIAL STATUS;

ANTINEOPLASTIC AGENTS; COSTS AND COST ANALYSIS; DEVELOPING COUNTRIES; HUMANS; INCOME; INDUSTRY; NEOPLASMS; POLITICS; POVERTY; SOCIAL CONDITIONS;

EID: 85019875619     PISSN: 20502877     EISSN: 20502885     Source Type: Journal    
DOI: 10.1080/20502877.2017.1314885     Document Type: Review

References (24)

1. Badwe R., Hawaldar R., Nair N., Kaushik R., Parmar V., Siddique S., Budrukkar A., Mittra I., and Gupta S., 2015. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer:An open-label randomised controlled trial. The Lancet Oncology, 16, pp. 1380–1388.
2. Bertolini F., Sukhatme V. P., and Bouche G., 2015. Drug repurposing in oncology — patient and health systems opportunities. Nature Reviews Clinical Oncology, 12, pp. 732–742.
3. Cherny N. I., Sullivan R., Dafni U., Kerst J. M., Sobrero A., Zielinski C., de Vries E. G., and Piccart M. J., 2015. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies:The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology, 26, pp. 1547–1573.
4. Clinton H. 2016. My vision for universal, quality, affordable health care. The New England Journal of Medicine, 375, pp. e36.
5. DiMasi J. A., Hansen R. W., and Grabowski H. G. 2003. The price of innovation:New estimates of drug development costs. Journal of Health Economics, 22, pp. 151–185.
6. Eniu A., Torode J., Magrini N., Bricalli G., Kutluk T., Barr R., Lopes G., Wagner C., and Shulman L. N., 2016. Back to the ‘essence’ of medical treatment in oncology:The 2015 WHO Model List of Essential Medicines. ESMO Open, 1, e000030.
7. FDA. Hematology/oncology (cancer) approvals & safety notifications. Available at:
8. Ferreira C. G., Achatz M. I., Ashton-Prolla P., Begnami M. D., Marchini F. K., and Stefani S. D., 2016. Brazilian health-care policy for targeted oncology therapies and companion diagnostic testing. The Lancet Oncology, 17, pp. e363–e370.
9. Garcia-Gonzalez P., Boultbee P., and Epstein D., 2015. Novel humanitarian aid program:The glivec international patient assistance program — lessons learned from providing access to breakthrough targeted oncology treatment in low- and middle-income countries. Journal of Global Oncology, 1, pp. 37–45.
10. Gyawali B., 2016. Me, too. Journal of Global Oncology, 2, pp. 99–104.
11. Gyawali B., Poudyal B. S., and Iddawela M., 2016. Cheaper options in the prevention of chemotherapy-induced nausea and vomiting. Journal of Global Oncology, 2, pp. 145–153.
12. Kantarjian H., 2016. The arrival of generic imatinib into the U.S. market:An educational event. The ASCO Post, May 25. Available at:.
13. Kantarjian H. M., Fojo T., Mathisen M., and Zwelling L. A., 2013. Cancer drugs in the United States:Justum Pretium — the just price. Journal of Clinical Oncology, 31, pp. 3600–3604.
14. Kerr D., and Elzawawy A., 2012. Targeted therapies:Manufacturer sponsorship bias in economic analyses matters. Nature Reviews Clinical Oncology, 9, pp. 309–310.
15. Kerr D. J., and Midgley R., 2010. Can we treat cancer for a dollar a day? Guidelines for low-income countries. New England Journal of Medicine, 363, pp. 801–803.
16. Le Tourneau C., Delord J. P., Goncalves A., Gavoille C., Dubot C., Isambert N., Campone M., Tredan O., Massiani M. A., Mauborgne C., Armanet S., Servant N., Bieche I., Bernard V., Gentien D., Jezequel P., Attignon V., Boyault S., Vincent-Salomon A., Servois V., Sablin M. P., Kamal M., Paoletti X., and Investigators. 2015. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA):A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. The Lancet Oncology, 16, pp. 1324–1334.
17. Moore M. J., Goldstein D., Hamm J., Figer A., Hecht J. R., Gallinger S., Au H. J., Murawa P., Walde D., Wolff R. A., Campos D., Lim R., Ding K., Clark G., Voskoglou-Nomikos T., Ptasynski M., Parulekar W., and National Cancer Institute of Canada Clinical Trials. 2007. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 25, pp. 1960–1966.
18. Obama B., 2016. United States health care reform:Progress to date and next steps. Journal of the American Medical Association, 316, pp. 525–532.
19. Prasad V. 2016. Perspective:The precision-oncology illusion. Nature 537, pp. S63–S63.
20. Rugo H. S., Barve A., Waller C. F., Hernandez-Bronchud M., Herson J., Yuan J., Manikhas A., Bondarenko I., Mukhametshina G., Nemsadze G., Parra J. D., Abesamis Tiambeng M. L. T., Baramidze K., Akewanlop C., Vynnychenko I., Sriuranpong V., Manillapalli G., Ray S., Yanez Ruiz E. P., and Pennella E. J. 2016. Heritage:A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin. Journal of Clinical Oncology, 34, 2016 (suppl; abstr LBA503).
21. Schnipper L. E., Davidson N. E., Wollins D. S., Tyne C., Blayney D. W., Blum D., Dicker A. P., Ganz P. A., Hoverman J. R., Langdon R., Lyman G. H., Meropol N. J., Mulvey T., Newcomer L., Peppercorn J., Polite B., Raghavan D., Rossi G., Saltz L., Schrag D., Smith T. J., Yu P. P., Hudis C. A., and Schilsky R. L., 2015. American Society of clinical oncology statement:A conceptual framework to assess the value of cancer treatment options. Journal of Clinical Oncology, 33, pp. 2563–2577.
22. Torre L. A., Bray F., Siegel R. L., Ferlay J., Lortet-Tieulent J., and Jemal A., 2015. Global cancer statistics, 2012. A Cancer Journal for Clinicians, 65, pp. 87–108.
23. West H. J. 2016. No solid evidence, only hollow argument for universal tumor sequencing:Show me the data. JAMA Oncology, 2, pp. 717–718.
24. Zalcman G., Mazieres J., Margery J., Greillier L., Audigier-Valette C., Moro-Sibilot D., Molinier O., Corre R., Monnet I., Gounant V., Rivière F., Janicot H., Gervais R., Locher C., Milleron B., Tran Q., Lebitasy M.-P., Morin F., Creveuil C., Parienti J.-J., and Scherpereel A., 2016. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS):A randomised, controlled, open-label, phase 3 trial. The Lancet, 387, pp. 1405–1414.